Milwaukee, WI Clinical Trials Report — May 2026

May 2026 brings a mix of urgent opportunities and fresh research avenues for Milwaukee residents considering participation in clinical trials. With 43 trials slated to conclude enrollment within the next 90 days, prompt action is essential for interested individuals, particularly those seeking opportunities as healthy volunteers.

Among these rapidly closing studies, 2 trials are still actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close. For patients managing specific health conditions, trials focused on various cancers and other serious conditions are also nearing their deadlines. Conditions with trials closing soon include:

• Pancreatic cancer (2 trials)
• Pancreatic ductal adenocarcinoma (2 trials)
• Cholangiocarcinoma (2 trials)
• Advanced solid tumor (1 trial)
• AML (1 trial)
• Atopic dermatitis (1 trial)
• ALL, adult (1 trial)
• Burkitt lymphoma (1 trial)
• Cerebral palsy (1 trial)
• Breast cancer (1 trial)

New Research Opportunities Emerge

This month, Milwaukee saw the opening of 5 new clinical trials, an increase from the 2 trials that launched in April 2026 and the 3 in March 2026. This brings the total number of actively recruiting clinical trials in Milwaukee, WI, to 642 across 180 research facilities, underscoring the city's active research landscape.

May brings several notable new trials to Milwaukee, including a significant Phase 3 study from a major sponsor. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• The Medical College of Wisconsin is sponsoring NCT07572929, "A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant." This Phase 2 investigation involves 450 participants and aims to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT).
• Also from the Medical College of Wisconsin, NCT07594886, "Left Atrial Pressure-Guided Heart Failure Optimization During Atrial Fibrillation Ablation (LAP AF-HF)," involves 300 participants. This study examines whether measuring blood pressure inside the left upper chamber of the heart during an atrial fibrillation ablation procedure can help identify patients who would benefit from heart failure medications.

New trials this month are exploring a range of conditions, with the most frequent being heart failure (2 trials), amnioinfusion (1 trial), atrial fibrillation (AF) (1 trial), catheter ablation (1 trial), chorioamnionitis affecting fetus or newborn (1 trial), diabetes during pregnancy (1 trial), guideline implementation (1 trial), myelodysplastic syndromes (1 trial), myeloid disorders (1 trial), and myeloproliferative neoplasm (1 trial). The new studies include 3 "OTHER" type trials, 2 device trials, and 2 drug trials, along with 1 behavioral and 1 dietary supplement trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research in Milwaukee. While 0 of the 5 new trials launched this month are actively seeking healthy volunteers, a total of 45 clinical trials across Milwaukee are currently recruiting healthy participants, providing avenues for those interested in supporting medical research.

Milwaukee's Leading Research Facilities

Milwaukee is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Medical College of Wisconsin (237 trials)
• Aurora Sinai Medical Center (54 trials)
• Aurora Saint Luke's Medical Center (52 trials)
• Aurora Cancer Care-Milwaukee (49 trials)
• Children's Hospital of Wisconsin (42 trials)
• Research Site (25 trials)
• Froedtert Hospital & the Medical College of Wisconsin (19 trials)
• Children's Wisconsin (18 trials)
• Froedtert Hospital (16 trials)
• Ascension Columbia Saint Mary's Hospital - Milwaukee (15 trials)
• Froedtert Hospital and the Medical College of Wisconsin (14 trials)
• Aurora St. Luke's Medical Center (12 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at the Medical College of Wisconsin and Froedtert Hospital, to specialized care at Aurora Cancer Care-Milwaukee and Children's Hospital of Wisconsin.

Broadening Your Search: Nearby Options

While Milwaukee offers a significant array of clinical trial opportunities, individuals may also find options in nearby communities within Wisconsin. Cities with active trials include Madison (6 trials), Wausau (2 trials), Appleton (1 trial), Green Bay (1 trial), Marshfield (1 trial), and Waukesha (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 5 new trials launched this month, 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is female-only, while 0 include children or are male-only. Academic institutions continue to play a vital role in Milwaukee's research ecosystem, with the Medical College of Wisconsin sponsoring 4 of the new studies. Industry sponsors like Novo Nordisk A/S are also driving significant research efforts with 1 new trial.

As we move through May, Milwaukee's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and explore new treatment options.